Clients
Testimonial
Joseph Amprey, III, M.D., Ph.D., Former Chief Business Officer, Zyngenia, Inc.
“After working with Jamie for more than three years at MedImmune, I was excited to bring her on as a consultant at New Enterprise Associates when she started PressComm PR. Jamie is an incredibly talented communications professional, with the ability to see the big picture and offer strategic insights while also being able to provide strong attention to detail. Whether you need a full-scale healthcare communications campaign, support for press releases and media outreach, or objective insight into the effectiveness of your communications materials, I’d highly recommend Jamie for your communications projects.”
“It is a pleasure working with a professional such as Jamie Lacey-Moreira. She is smart, quick and is always current. Jamie knows how to reach the key decision makers and really knows how to get your organization’s name out there. Her promotional efforts for Women In Bio have been fantastic and she has helped us reach new levels of professionalism!”
“Jamie is an excellent business partner and collaborator. I’ve come to rely on her expertise in areas far beyond our original scope. She’s entrepreneurial and creative, with an eye for detail. She’s a valued and trusted advisor.”
“Jamie’s presentation to a group of federal government representatives was right on target and much appreciated by the meeting facilitator and participants. I love working with Jamie.”
Sample list of clients:
Gliknik Inc. — Founded in 2007, Gliknik is a biotechnology company making new therapies for patients with cancer and autoimmune/inflammatory diseases. Its mission is to discover, develop and bring to market truly novel therapies. Its expertise is modulation of the immune system. Gliknik is based at the University of Maryland BioPark, Baltimore, Maryland. In 2009, Gliknik was named Maryland Best New Incubator Company of the Year. For more information, visit www.gliknik.com.
GlycoMimetics, Inc. — Founded in 2003, GlycoMimetics is developing small molecule drugs targeting unmet clinical needs in orphan disease indications. The Company’s lead product, GMI-1070, is initially being developed for the treatment of vaso-occlusive crisis in sickle cell disease and has been granted Orphan Drug and Fast Track Status by the U.S. Food and Drug Administration. Phase 1 clinical trials and a pilot study in sickle cell patients are complete. A Phase 2 trial in vaso-occlusive crisis (“VOC”) in sickle cell disease began enrolling in 2010. GMI-1070 is also being evaluated in preclinical studies for use in other orphan indications. For additional information, please visit the company’s web site: www.glycomimetics.com.
New Enterprise Associates (NEA) — a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same core principles: supporting its entrepreneurs, providing an excellent return to its limited partners, and practicing its profession with the highest standards and respect. Through its affiliated funds, NEA focuses on investments at all stages of a company’s development, from seed stage through IPO. With approximately $8.5 billion in committed capital, NEA’s experienced management team has invested in over 650 companies, of which more than 160 have gone public and more than 250 have been acquired. NEA has U.S. offices in Chevy Chase, Maryland; Menlo Park, California; and Baltimore, Maryland. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.
UM BioPark — The BioPark is a biomedical research park on the vibrant academic medical center campus of the University of Maryland, Baltimore (UMB). Its community of life science companies and academic research centers are commercializing new drugs, diagnostics and devices and advancing biomedical research. For more information, please visit, www.umbiopark.com.
Zyngenia, Inc. — Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of next- generation multi-specific antibodies. The company uses proprietary patented technology to engineer single molecular entities that may interact with two or more targets. The company will initially focus its ZybodyTM development on therapies for various cancers and autoimmune disorders. Zyngenia is headquartered in Gaithersburg, Maryland. For more information, visit www.zyngenia.com.